Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. reports news on its global medtech business, which supplies hospitals, physician offices and other care settings with connected solutions, medical devices and advanced injectable technologies. Company updates commonly cover results from continuing operations following the Kidney Care divestiture, portfolio activity in infusion therapies and platforms, surgical tables, smart stretchers, patient-support systems, monitoring tools, and hemostatic and sealing agents.
Baxter announcements also address product introductions such as the IV Verify Line Labeling System, conference showcases for Global Surgical Solutions, Advanced Surgery and Patient Support Systems, annual-meeting matters, executive finance leadership, and foundation partnerships tied to healthcare settings.
Baxter International (NYSE:BAX) acknowledges the results of a multicenter study from the OxirisNet Registry, focusing on COVID-19 patients treated with the Oxiris filter. The study indicated a significant reduction in serum IL-6 levels and improvements in organ function, correlating with a decrease in ICU mortality rates compared to historical controls. However, due to the study's observational design, no causal relationships can be established. The findings emphasize the potential of Oxiris in treating critically ill patients, paving the way for further research.
Baxter International Inc. (NYSE:BAX) supports findings from an ongoing study on critically ill COVID-19 patients, demonstrating the importance of indirect calorimetry in accurately assessing nutritional needs in ICU settings. The study, which analyzed 22 patients over 21 days, revealed that traditional predictive equations significantly understate patients' resting energy expenditure (REE). Notably, after the first week, average REE was 150% of predictions, with some cases reaching double. These findings underscore the risks associated with both over- and under-feeding in this vulnerable population.
Baxter International (NYSE:BAX) will present at the 29th Annual Credit Suisse Virtual Healthcare Conference via webcast on November 9, 2020. Jay Saccaro, the CFO, is set to speak at 11:45 a.m. Eastern Time. Investors and interested parties can access the live presentation and replay through November 9, 2021, on www.baxter.com. Baxter's extensive portfolio of medical products supports millions of patients and healthcare providers globally, emphasizing their commitment to transformative healthcare innovations.
Baxter International Inc. (NYSE:BAX) supports interim findings from a study on the nutritional needs of COVID-19 patients in ICU, which highlights the inaccuracies of predictive equations in estimating energy requirements. The study of 22 U.S. patients indicates that patients experienced progressive hypermetabolism and variability in resting energy expenditure (REE) over their ICU stay. Baxter's Q-NRG+ technology aims to address these challenges by providing accurate and personalized nutrition insights, essential for improving patient outcomes.